Drug intelligence / Profile preview

t4 endonuclease v

Development stage
Phase 3
Lead developer
Applied Genetics Inc. Dermatics
Modality
Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration
Topical, Ophthalmic
01

Overview

T4 endonuclease V is a DNA repair enzyme originally derived from the T4 bacteriophage. It specifically targets cyclobutane pyrimidine dimers (CPDs), which are the most prevalent DNA lesions induced by ultraviolet (UV) radiation. The enzyme possesses a dual catalytic mechanism: it acts as a DNA glycosylase, cleaving the glycosidic bond of the 5' pyrimidine of the dimer, followed by an AP-lyase activity that cleaves the phosphodiester bond. In clinical development, the enzyme is typically encapsulated in pH-sensitive liposomes (referred to as T4N5 liposomes) to enable delivery into the cytoplasm and subsequently the nuclei of keratinocytes. It has been primarily investigated as a chemopreventive agent to reduce the incidence of actinic keratosis and non-melanoma skin cancers, particularly in high-risk populations such as patients with xeroderma pigmentosum (XP).

Brand names
Dimericine
Other names
denV gene productT4N5 liposome lotionT-4N5 liposome lotionT 4N5 liposome lotionCyclobutane pyrimidine dimer-DNA glycosylaseT4-VT-4-VT 4-V
02

Targets

CPD (Cyclobutane pyrimidine dimer DNA lesion)

Beyond the preview

Go deeper on t4 endonuclease v.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on t4 endonuclease v.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call